吉西他滨联合卡培他滨治疗难治性乳腺癌的临床观察

目的观察吉西他滨联合卡培他滨（GX方案）治疗术后复发的乳腺癌患者的疗效和不良反应。方法50例患者分别接受GX方案化疗3～6个周期，按世界卫生组织（WHO）标准评价疗效及不良反应。结果50例患者均可评价，其中完全缓解（CR）4例（8．0％），部分缓解（PR）22例（44．0％），稳定（SD）18例（36．0％），进展（PD）6例（12．0％）。中位肿瘤进展时间（mTTP）为8．3个月（95％CI：6．55—10．89），中位总生存时间（mOS）为18．0个月（95％CI：14．34～21．98）。主要不良反应为骨髓抑制和皮疹。结论GX方案治疗晚期乳腺癌安全有效，不良反应较轻，值得临床推广应用。

Clinical observation of gemcitabine plus capecitabine in treatment of 50 metastatic breast cancer patients

Objective To evaluate the results of combination chemotherapy with gemcitabine plus capecitabine in the treatment of metastatic breast cancer.Methods 50 patients with metastatic breast cancer accepted gemcitabine plus capecitabine chemotherapy.Response and side effect were evaluated by WHO standard methods.Results Among 50 cases who could be evaluated,4 patients achieved complete response(CR),22 patients achieved partial response(PR),18 patients had no change(NC),6 patients had progressive disease(PD),median time to progression was 8.3(95%CI:6.55-10.89)months and median overall survival time was 18.0(95%CI:14.34-21.98)months.The major adverse events were bone marrow suppression and skin rash.Conclusions Gemcitabine plus capecitabine is effective and well tolerated for metastatic breast cancer,it gives us a new choice.